This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

▼ Wegovy® goes beyond


Learn more about Wegovy® benefits in reducing of heart attack, stroke and cardiovascular death observed in the SELECT trial.3


Components of 3 point MACE*
*(major adverse cardiac events)


Wegovy® (semaglutide injection 2.4 mg) is the first once-weekly GLP-1 RA* indicated for weight management, helping your patients obtain a 16.7% (17.6 kg) mean weight loss sustained over 2 years.**4,5

 

*GLP-1 RA, glucagon-like peptide-1 receptor agonist.
**At 104 weeks, mean weight loss was 16.7% vs. 0.6% with placebo in the STEP 5 trial5

  
{{answer.value}}%

Connecting medical professionals to the tools they need to manage obesity effectively.
Rethink Obesity

Discover obesity congresses

Stay up-to-date, network with your peers and connect with leading experts from around the world. Get an overview of our obesity congresses and join us as we dive into the latest research and scientific advancements in the field of obesity.

1.

Carterson I.D., Alfadda A.A., Auerbach P. et al. Gasp to bridge: Misalignment between preception, reality and actions in obesity. Diabetes Obes Metab. 2019; 21:1914-1924.

2.

James W. Who recognition of the global obesity epidemic. International Journal of Obesity. 2008;32(S/):S120-S126.

3.

Lincoff AM et al. N Engl J Med 2023;D&I:10.1056/NEJMoa2307563.

4.

Wegovy® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; 2024.

5.

Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.

1.

Carterson I.D., Alfadda A.A., Auerbach P. et al. Gasp to bridge: Misalignment between preception, reality and actions in obesity. Diabetes Obes Metab. 2019; 21:1914-1924.

2.

James W. Who recognition of the global obesity epidemic. International Journal of Obesity. 2008;32(S/):S120-S126.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

 

 

HQ23OB00107, April 2023